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• Patients with PBC have higher AE2 CpG methylation
in upstream AE2a and/or AE2b2/AE2b1 promoter
regions in liver and PBMCs.
• Combined methylation rates of 2 minimal CpG-clus-
ters in the liver and 1 minimal CpG-cluster in
PBMCs specifically distinguished PBC from normal
and diseased controls.
• Methylation rates of AE2 promoter regions inversely
correlated with levels of respective AE2 mRNAs in
liver and PBMCs.
• Alternate AE2b2/AE2b1 promoter regions were found




Primary biliary cholangitis (PBC) is a chronic immune-
associated cholestatic liver disease with unclear com-
plex/multifactorial etiopathogenesis affecting mostly
middle-aged women. Patients with PBC exhibit
reduced expression of the AE2/SLC4A2 gene. Herein,
we found that AE2 promoter regions are hypermethy-
lated in the liver and peripheral blood mononuclear
cells of patients with PBC. This increased methylation
is associated with downregulated AE2-gene expres-
sion, which might contribute to the pathogenesis of
PBC. Therefore, novel epigenetic targets may improve
treatment in patients with PBC who respond poorly to
current pharmacological therapies.
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Background & Aims: Patients with primary biliary cholangitis (PBC) exhibit reduced AE2/SLC4A2 gene expression in the liver
and peripheral blood mononuclear cells (PBMCs). AE2 encodes a Cl–/HCO3– exchanger involved in biliary bicarbonate secretion
and intracellular pH regulation. Reduced AE2 expression in PBC may be pathogenic, as Ae2-knockout mice reproduce charac-
teristic PBC features. Herein, we aimed to identify CpG-methylation abnormalities in AE2 promoter regions that might contri-
bute to the reduced gene transcription in PBC livers and PBMCs.
Methods: CpG-cytosinemethylation rates were interrogated at 1-base pair resolution in upstream and alternate AE2 promoter
regions through pyrosequencing of bisulphite-modified genomic DNA from liver specimens and PBMCs. AE2a and alternative
AE2b1 and AE2b2 mRNA levels were measured by real-time PCR. Human lymphoblastoid-T2 cells were treated with 5-aza-2´-
deoxycytidine for demethylation assays.
Results: AE2 promoters were found to be hypermethylated in PBC livers compared to normal and diseased liver specimens.
Receiver operating characteristic (ROC) curve analysis showed that minimal CpG-hypermethylation clusters of 3 AE2a-CpG
sites and 4 alternate-AE2b2-CpG sites specifically differentiated PBC from normal and diseased controls, with mean methyla-
tion rates inversely correlating with respective transcript levels. Additionally, in PBMCs aminimal cluster of 3 hypermethylated
AE2a-CpG sites distinguished PBC from controls, and mean methylation rates correlated negatively with AE2a mRNA levels in
these immune cells. Alternate AE2b2/AE2b1 promoters in PBMCs were constitutively hypermethylated, in line with absent
alternative mRNA expression in diseased and healthy PBMCs. Demethylation assays treating lymphoblastoid-T2 cells with 5-
aza-2´-deoxycytidine triggered AE2b2/AE2b1 expression and upregulated AE2a-promoter expression.
Conclusions: Disease-specific hypermethylation of AE2 promoter regions and subsequent downregulation of AE2-gene
expression in the liver and PBMCs of patients with PBCmight be critically involved in the pathogenesis of this complex disease.
© 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Primary biliary cholangitis (PBC), formerly named primary biliary
cirrhosis,1 is a chronic cholestatic liver disease mostly affecting
middle-aged women, in which portal mononuclear infiltrates
result in progressive damage and destruction of interlobular bile
ducts.2–5 Thus far, the etiopathogenesis of PBC remains elusive.
The disease is regarded as a complex multifactorial disease that
may be triggered by environmental factors in individuals with
genetic predisposition.6 Genome-wide-association studies
(GWAS)7–10 and dense fine-mapping association studies11 have
related susceptibility to PBC with genetic variations in genes perti-
nent to immunity like HLA type II, IL12A, IL12RB2 , IL21 and IL21R
genes among others. Certainly, the disease is strongly associated
with autoimmune phenomena, such as the presence of autoreac-
tive T cells in portal infiltrates and high-titer serum antimitochon-
drial autoantibodies (AMA) that recognize antigens at the inner
mitochondrial membrane. Notwithstanding these features ofKeywords: AE2 chloride/bicarbonate exchanger; cholestasis; DNA methylation;
epigenetic repression; primary biliary cholangitis/cirrhosis.
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2019;autoimmunity in PBC, the therapeutic regimes with potent immu-
nosuppressants have shown little efficacy, which is particularly
intriguing if compared with the substantial benefit obtained in
most patients with early PBC undergoing therapywith ursodeoxy-
cholic acid (UDCA).12–16 Since the hydrophilic bile acid UDCA is
known to induce bicarbonate-rich choleresis, we have been postu-
lating that primary or secondary abnormalities in the mechanisms
responsible for biliary bicarbonate secretion might have a patho-
genic role in PBC.17–21 Indeed, positron-emission-tomography stu-
dies showed that untreated patients with PBC failed to increase
biliary bicarbonate in response to secretin, while treatment with
UDCA for a few months could reverse this defect.19
In humans, secretin-stimulated biliary bicarbonate secretion is
crucial for adequate bile modifications along the biliary tract.21–24
Bicarbonate secretion occurs at the apical membrane of bile-duct
cells via electroneutral Na+-independent Cl–/HCO3– anion
exchange (AE), which can be stimulated by cAMP, the second
messenger for secretin signal transduction.22 AE2/SLC4A2 gene-
silencing experiments indicated that AE2 is the main carrier for
this activity in cholangiocytes.25–27 Previously, we reported that
bile-duct cells isolated from PBC patients exhibit defective
cAMP-stimulated AE activity,20 and that PBC livers have dimin-
ished AE2 expression at the luminal membrane of the biliary
epithelium.18 Also, we reported that AE2 mRNA levels are
decreased in liver biopsies and peripheral blood mononuclear
Research Articlecells (PBMCs) from patients with PBC.17 The notion that dimin-
ished AE2 might be involved in PBC pathogenesis received defi-
nite support from our findings in Ae2-knockout mice, which
exhibit characteristic features resembling PBC.28–30
Conventional genotyping of selected AE2/SLC4A2 tag single-
nucleotide polymorphisms (rs2069443, rs2303933, rs2303937,
and rs2303941) in Japanese patients with PBC revealed associa-
tions with disease susceptibility and/or anti-centromere antibody
production.31 But in Caucasian patients, no association between
variations in AE2/SLC4A2 and PBC susceptibility has been
reported, though single-nucleotide polymorphism analyses
across this gene have found 2 variants influencing AMA status.32
Also, a synonymous variation in exon 6 (rs2303932) was related
with the progression of the disease in a French population.33
More recent findings provided evidence for upregulation of
microRNA 506 in PBC bile-duct cells being involved in the
decreased liver expression of AE2 protein through blocking
the translation (but not the transcription) of AE2 messages.34
However, the genetic and/or epigenetic factors responsible
for the decreased AE2 mRNA expression in PBC17 remain to be
fully elucidated. Since hypermethylation of CpG-cytosines in pro-
moter regions is a frequent mechanism for transcriptional
inactivation,35–37 we explored these possible variations in AE2/
SLC4A2 promoter regions. Thus, we analyzed the methylation
rates of proximal CpG-cytosines in the widely expressed
upstream promoter AE2a and in the tissue-restricted alternate
overlapping AE2b2/AE2b1 promoter regions (located within
intron 2 of the AE2/SLC4A2 gene),38,39 in liver and PBMC samples
from patients with PBC and normal and diseased controls. Addi-
tionally, we determined the correlation between methylation
rates in AE2 promoters and the levels of respective AE2 mRNAs
in these samples.
Patients and methods
Human samples and patients
Liver specimens (n = 20) and PBMCs (n = 16) from patients with
PBC were obtained at the Clinic University of Navarra (Pamplona)
and the Hospital Clinic (Barcelona) before patients started their
treatment with UDCA. Liver specimens were frozen samples of
either diagnostic liver biopsies or pieces of liver explants from
patients transplanted because of advanced PBC. Diagnosis of
PBC was based on biochemical cholestasis, AMA positivity (as
determined by immunofluorescence), and compatible histology –
presymptomatic forms with normal alkaline phosphatase were
also considered – (see Table 1 for patient characteristics andTable 1. Main characteristics of the PBC-patient cohorts⁎








ALP, serum alkaline phosphatase; ALT, serum alanine aminotransferase; AST, serum aspa
cholangitis; PBMCs, peripheral blood mononuclear cells.
*The most relevant characteristics of the 2 different populations of patients with PBC from
patients fromwhom normal liver samples were obtained (6 female and 8 male) was 58.2 y
healthy volunteers/blood-donors after being completely anonymized.
JHEP Reports vobiochemical parameters). Pieces of liver explants from patients
transplanted because of other liver diseases (OLDs) (n = 24) and
PBMCs from additional patients with OLDs (n = 25) were included
in the study as non-PBC diseased controls (see Table 2 for patient
characteristics and biochemical parameters). The 24 patients
with OLDs from whom liver explants were obtained were further
split into patients with either moderate or severe cholestasis
according to biochemical parameters, as detailed in Table S1. Addi-
tionally, normal bordering tissue samples (n = 14) obtained from
surgery dissection of metastatic tumors in the liver were included
as normal liver controls (NL). PBMCs used as normal controls
(n = 16) were anonymized samples obtained from healthy
blood-donors/volunteers (HVs). All patients gave written informed
consent for the study, which was approved by the institutional
Ethics Committees, in compliance with the ethical principles of
the Declaration of Helsinki.
Assessment of genomic-DNA methylation and mRNA
expression
Genomic DNA (gDNA) and total RNA from liver specimens were
extracted with an RNA/DNA Extraction Kit (QIAGEN), while a
TRI-Reagent solution (Sigma) was used for both extractions
from PBMC samples. DNA methylation rates in proximal AE2 pro-
moter regions (upstream AE2a promoter and alternate AE2b1 and
AE2b2 promoters within intron 2)38,39 were obtained at 1-base
pair resolution by pyrosequencing. Briefly, gDNA aliquots (1 μg)
were treated overnight with bisulphite (EpiTect-Bisulphite Kit
from QIAGEN) and used as template for PCR amplification with
primers that match non-CpG regions within the bisulphite con-
verted promoter sequences (see Table S2). 5’-biotinylated reverse
primers allowed for resultant amplicons to be immobilized onto
streptavidin-coated beads, followed by denaturation in 0.5 M
NaOH, and sequencing of biotinylated reverse strands with
respective forward primers (using a PyroMarkTM Q96 pyrose-
quencer and PyroQ-CpGTM 1.0.9 software; Biotage-QIAGEN).
The levels of mRNAs were assessed by real-time PCR in an iCy-
cler iQ5 (BioRad), using reverse-transcribed total RNA and speci-
fic primers for AE2a, AE2b1 and AE2b2, and for GAPDH as
normalizing control (Table S3). For calculations, we used the
Livak/Schmittgen’s method,40 though modified after estimating
an average amplification efficiency of 80%, i.e. 1.8–ΔΔCT.
Lymphoblastoid-T2 cells
Human T2 cells (174xCEM.T2) – hybrid from B and T lympho-
blasts – were cultured in RPMI with 25 mM Hepes, 10% fetal
bovine serum, and penicillin/streptomycin (Gibco-Invitrogen).± SD) PBMC specimens, n = 16 (mean ± SD)
18:2 15:1
± 13.1 52.5 ± 8.0
± 430.7 489.5 ± 308.4
± 270.1 147.8 ± 252.4
± 34.8 46.0 ± 32.7
± 28.7 40.6 ± 35.7
.4 ± 2.2 0.8 ± 0.4
rtate aminotransferase; GGT, serum gamma glutamyltransferase; PBC, primary biliary
whom either liver samples or PBMCs were obtained, are indicated. The mean age of
ears (SD: ± 12.9). The PBMC samples employed as normal controls were obtained from
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Table 2. Main characteristics of patients with OLDs⁎
Patients with OLDs from whom liver specimens were obtained
Patients (female/male) Age (years) ALP (IU/L) GGT (IU/L) ALT (IU/L) AST (IU/L) Bilirubin (mg/dl)
ALD 0 / 13 56.1 ± 9.4 329.3±190.7 103.1 ± 99.7 41.1 ± 19.0 56.2 ± 19.8 3.8 ± 1.9
NAFLD 2 / 2 58.9 ± 11.7 275.8 ± 92.3 199.8 ± 61.2 117.3 ± 81.6 41.7 ± 14.6 0.7 ± 0.4
TxH 0 / 1 70.7 1632.0 914.0 77.0 80.0 5.4
VHC 0 / 3 59.7 ± 16.6 131.0 ± 30.1 33.3 ± 21.5 44.0 ± 19.3 22.7 ± 2.1 0.9 ± 0.5
PSC 0 / 1 54.6 1598.0 309.0 52.0 48.0 5.6
SBC 1 / 1 68.5 ± 4.5 574.5±632.9 103.0±108.9 12.0 ± 5.7 16.5 ± 3.5 1.0 ± 0.4
Patients with OLDs from whom PBMC specimens were obtained
Patients (female/male) Age (years) ALP (IU/L) GGT (IU/L) ALT (IU/L) AST (IU/L) Bilirubin (mg/dl)
ALD 1 / 10 57.6 ± 5.9 202.6 ± 59.2 31.4 ± 14.7 16.2 ± 10.4 28.5 ± 9.7 5.6 ± 4.3
NAFLD 0 / 1 46.0 109.0 38.0 70.0 28.0 1.4
TxH 1 / 0 45.0 1321.0 815.0 71.0 76.0 5.1
VHC 5 / 5 57.5 ± 13.8 124.9 ± 33.6 24.7 ± 18.0 61.7 ± 45.8 44.1 ± 34.0 0.6 ± 0.3
PSC 0 / 1 55.0 184.0 39.0 10.0 24.0 4.5
SBC 0 / 1 59.0 133.5 27.0 9.5 22.5 4.1
ALD, alcohol-related liver disease; ALP, serum alkaline phosphatase; ALT, serum alanine aminotransferase; AST, serum aspartate aminotransferase; GGT, serum gamma glutamyl-
transferase; NAFLD, non-alcoholic fatty liver disease; OLDs, other liver diseases; PBMCs, peripheral blood mononuclear cells; PSC, primary sclerosing cholangitis; SBC, secondary
biliary cirrhosis; TxH, toxic hepatitis; VHC, viral hepatitis C.
*The most relevant characteristics (mean ± SD) of patients with OLDs fromwhom either liver samples or PBMCs were obtained, are indicated. Each OLD population was classified
according to the ethology.Cells (1x105/well) were treated for 48 and 72 h with and without
the demethylating agent 5-aza-2´-deoxycytidine (2 μM, Sigma) or
the histone-deacetylase inhibitor trichostatin-A (300 nM; Sigma).
Nucleic acids were extracted and analyzed as described above for
PBMCs.
Statistics
Data are shown as mean ± SD unless otherwise indicated. Statis-
tical analyses were performed by using the GraphPad Prism-5
software (San Diego, CA). Because the number of analyzed sam-
ples was usually ~20 for each group, non-parametric tests were
regularly employed (even though, according to D’Agostino-Pear-
son test, there were variables showing normally distributed
values). Differences between PBC, OLD and normal control sam-
ples were analyzed with Kruskall-Wallis test followed by Mann-
Whitney U test to analyze the differences between 2 groups.
The Spearman's rank-correlation coefficient rswas also determined
when pertinent. Two-tailed p values <0.05 were considered statis-
tically significant. Receiver (or Relative) operating characteristic
(ROC) curves were constructed and the area under ROC curves
(AUC) was calculated to evaluate sensitivity and specificity of mul-
tiple CpG-dinucleotide sets within AE2 promoters. The criteria to
obtain differentiating CpG-site combinations were ROC curves
with p <0.05when PBCwas comparedwith bothNL andOLD livers,
and ROC curves with p >0.05 for comparisons between OLD and
normal livers. The cut-off points on the ROC curves at which accu-
racy of PBC detection was maximal, were selected.
Results
CpG-methylation analysis of AE2 promoters in liver samples
Pyrosequencing of the proximal AE2a promoter region encom-
passing 18 CpG sites in liver gDNA revealed increased average
methylation in PBC livers (24.01 ± 9.60%) compared to NL sam-
ples (10.78 ± 4.07%, p <0.001) and OLD specimens (13.19 ±JHEP Reports vo7.31%, p <0.005), while no significant differences were observed
between OLD and NL samples (see also heat-map representa-
tions41 in Fig. 1). Because alternative transcriptional activity is
normally prominent in the human liver,39 alternate AE2b2/
AE2b1 overlapping promoter regions were also analyzed in liver
gDNA. Similarly to our observations for AE2a, pyrosequencing of
18 CpG sites in AE2b2 and 7 CpG sites in AE2b1 regions indicated
that average methylation rates in PBC (65.71 ± 11.05% for AE2b1
and 49.14 ± 7.03% for AE2b2) were increased compared to NL
samples (56.72 ± 8.99% for AE2b1, p <0.05, and 38.55 ± 7.22% for
AE2b2, p <0.001) and OLD specimens (56.66 ± 10.17% for AE2b1,
p <0.01, and 40.43 ± 7.38% for AE2b2, p <0.001, whereas no signif-
icant differences were observed between NL and OLD liver sam-
ples (see also heat maps in Fig. 1).
AE2 CpG-methylation signatures in PBC livers
We then searched for minimal clusters of AE2 CpG methylation
that could specifically discriminate the PBC condition from both
normal andOLD controls.We therefore analyzed averagemethy-
lation rates of all possible combinations of assessed CpG sites,
and performed ROC curve analysis of differentiation between
PBC, NL and OLD livers. As illustrated in Fig. 2A-B, 2 minimal
CpG clusters, one relative to the AE2a promoter (–274a, –254a,
and –249a sites), and the other relative to the AE2b2 alternate
promoter (–307b2, –280b2, –263b2, and –261b2 sites), gave
highly significant ROC curves, with the highest fraction of PBC
samples correctly identified as positive (i.e. highest sensitivity)
and with the highest fraction of non-PBC samples correctly iden-
tified as negative (i.e. highest specificity). As expected, average
methylation rates of these 2 clustered CpG sites were signifi-
cantly higher in PBC than in normal and diseased controls
(Fig. 2C-D). Noticeably, the hypermethylated CpG sites of the
AE2b2 minimal cluster (–307b2, –280b2, –263b2, and –261b2
sites) are surrounding an HNF4 motif,39 closely upstream of the
HNF1 site,25,42 in the AE2b2 alternate promoter (see Fig. 1,l. 1 | 145–153 147
Fig. 1. Heat maps of CpG-methylation rates for AE2 promoter regions in the liver. The methylation rates of CpG-cytosines within interrogated proximal regions
of the upstream AE2a promoter (155-bp long; left panels), and alternate AE2b2 (477-bp; middle panels) and AE2b1 promoters (205-bp; right) were determined
through pyrosequencing of bisulphite-converted gDNA from NL specimens (n = 14), PBC-liver samples (n = 20, grouped by disease stages SI-IV), and liver
samples from patients with OLDs (n = 24). The upper diagrams show AE2 promoter regions with relevant sites and putative motifs for transcription factors, the
initial exons and the transcribed variants. Indicated CpG-dinucleotide positions, i.e. the negative numbers followed by either a, b1 or b2, are referred to cytosine
locations upstream to respective +1 position, i.e., A in ATG start codon in exon 2 for AE2a transcript, and in exons 1b1 and 1b2, for AE2b1 and AE2b2 mRNA
variants, respectively. Red-labeled numbers indicate hypermethylated CpG sites conforming the PBC-associated methylation signatures of minimal clusters.
Maps were obtained with the online Genesis software (http://genome.tugraz.at/serverclient/serverclient_download.shtml, originally designed at Graz University
of Technology for microarray data; cf. ref.41). Here, the highest and lowest methylation-rate values – among all values obtained for every CpG site – were
normalized in such a way that they ranged from 100% (light red) to 0% (light green) for each site (in accordance with respective color bars below). ALD, alcohol-
related liver disease; bp, base pair; gDNA, genomic DNA; NAFLD, non-alcoholic fatty liver disease; NL, normal liver; OLDs, other liver diseases; PBC, primary
biliary cholangitis; PSC, primary sclerosing cholangitis; SBC, secondary biliary cirrhosis; TxH, toxic hepatitis; VHC, viral hepatitis C.
Research Articleupper diagram). Additional ROC curve analysis combining the 2
minimal CpG clusters of AE2a and AE2b2 promoters resulted in
the highest AUC (Fig. S1). ROC curve analyses, therefore, allowedJHEP Reports vous to differentiate the PBC condition from the controls (NL and
OLD) with high sensitivity, specificity and accuracy. Altogether,
our data support the notion that, in the liver, AE2 promoterl. 1 | 145–153 148
Fig. 2. PBC-associated methylation signatures of minimal CpG-site clusters differentiating PBC from NL and OLD liver samples. Highly significant ROC curves
were obtained for average methylation of (A) a minimal CpG cluster within the AE2a promoter region (–274a, –254a, and –249a sites), and (B) another minimal
cluster within the AE2b2 alternate promoter (–307b2, –280b2, –263b2, and –261b2 sites); both ROC curve analyses also included comparisons of PBC versus NL
+OLD cohort (non-PBC samples). Analyses always resulted in the highest fraction of PBC samples correctly identified as positive and with the highest fraction of
non-PBC samples correctly identified as negative (highest sensitivity and highest specificity, respectively). Box plots to the right (each with minimum value, the
first quartile, the median, the third quartile, and the maximum value) graphically depict the comparisons, between PBC and control liver samples, of average
methylation rates of PBC-associated minimal CpG clusters in (C) AE2a promoter (–274a, –254a, and –249a sites), and in (D) AE2b2 alternate promoter (–307b2, –
280b2, –263b2, and –261b2 sites). Significant p values (<0.05) were obtained by Kruskall-Wallis test followed by Mann-Whitney U test. NL, normal liver; PBC,
primary biliary cholangitis; OLD, other liver disease.regions possess hypermethylation signatures of clustered CpG
sites which are able to distinguish PBC from both NL and OLD.
Gender and AE2 promoter hypermethylation
The female preponderance in PBC is remarkable –worldwide, the
ratio of affected females to males is as high as 10:1.43 Recently,
DNA-methylation sex differences were reported for a series of
genes and intergenic regions in the human liver.44 We therefore
decided to compare average methylation rates of the PBC-
associated CpG clusters in NL from females with those from
males, and found no differences, while highly significant differ-
ences were observed among females between NL and PBC
(Table S4). This indicates gender is not a determinant factor for
the hypermethylation changes detected in PBC specimens.
Negative correlations between mRNA levels of AE2 isoforms
and methylation rates within respective promoter regions in
liver samples
qPCR analysis of the 3 AE2 mRNA isoforms showed their levels
were significantly lower in PBC livers than in NL samples
(p <0.001 for both AE2a and AE2b2 mRNAs and p <0.05 for
AE2b1 mRNA). Concerning the mRNA levels in our current OLD
samples (n = 24), they weremarkedly lower in the specimen sub-
set from patients with advanced and severe cholestasis (n = 16,
Table S1 and Fig. S2), whereas in samples from patients with
moderate cholestasis (n = 8, Table S1) the mRNA levels were sig-
nificantly higher (Fig. S2). In PBC specimens, however, the AE2
mRNA levels were always consistently diminished, regardless of
whether patients had severe or moderate cholestasis (Fig. S2).
To assess whether diminished AE2 gene expression was asso-
ciated with increased promoter methylation we performed corre-
lation analyses between the levels of AE2 mRNA isoforms and
average CpG methylation rates. Significant negative correlations
were obtained for the cohort including all liver samples, i.e. in
the PBC+NL+OLD cohort (Table S5). Correlation coefficients were
higher in the cohort including PBC livers and NL samples only
(PBC+NL cohort, with no OLDs samples), while analysis of the
cohort with just OLD and NL samples (without PBC samples)
gave no significant correlations (Table S5). In fact, theJHEP Reports vomethylation rates of AE2 promoter regions in the liver subset of
severely cholestatic patients with OLDs were in the range of
those in patients with OLDs and moderate cholestasis (Fig. S3),
despite the encountered differences in AE2mRNA levels between
the 2 OLD subsets (Fig. S2). These data concur with the view that
the diminished AE2 expression observed in the former OLD sub-
set is unrelated to CpG methylation but due to severe cholestasis,
while the diminished liver expression of AE2mRNAs in PBC livers
appears to be amply justified by the increased CpG methylation
in AE2 promoter regions.
AE2 CpG methylation and AE2 mRNA expression in PBMCs
Pyrosequencing analysis of the AE2a promoter in PBMCs showed
>2-fold increased average methylation in PBC (20.18 ± 8.83%)
compared to healthy and diseased controls (HVs 7.16 ± 1.37%
and OLDs 9.22 ± 3.04%; p <0.01 each; see heat-map representa-
tions in Fig. 3A). ROC curve analysis of average methylation
rates of all possible combinations of assessed CpG sites revealed
a minimal cluster of 3 particular CpG-cytosines (at positions
−329a, −299a, and −291a) that specifically differentiated PBC
samples from both controls (Fig. 3B). Indeed, the average methy-
lation rate of these combined CpG sites was significantly higher in
PBC (26.0 ± 13.22) than in both healthy (7.75 ± 2.93; p <0.001)
and diseased controls (10.32 ± 7.48; p <0.001; Fig. 3C).
Quantitative-PCR analysis of PBMCs from 12 patients with
PBC, from 25 patients with OLDs and from 16 HVs showed consis-
tent expression of AE2a mRNA in all PBMC samples, while alter-
native AE2b1 and AE2b2 mRNA variants could hardly be
detected (not shown). In agreement with our previous findings,17
the levels of AE2amRNA in PBMCs were significantly diminished
in PBC compared to HV and OLD samples (p <0.01 each; Fig. S4).
Like liver tissue, negative correlations between AE2amRNA levels
and average methylation rates of AE2a promoter were observed
in cohorts with PBC and control samples (Table S6).
Pyrosequencing of alternate AE2b2 and AE2b1 promoter
regions in randomly selected PBMC gDNA samples from indivi-
duals with PBC and OLDs, and from HVs revealed consistent
methylation (Fig. S5). To investigate whether methylation of
alternate AE2b2/AE2b1 promoter regions might hinder thel. 1 | 145–153 149
Fig. 3. PBC-associated methylation pattern of AE2a promoter region in PBMCs. (A) Heat map of methylation rates of CpG sites within the interrogated AE2a
promoter in PBMCs from HVs (n = 16), patients with PBC (n = 16) and patients with OLDs (n = 25). Maps were obtained and normalized as described in Fig. 1
for the AE2 promoter regions in the liver; here, normalization color bars locate to the right. (B) Highly significant ROC curves obtained for a minimal cluster of
methylated CpG sites within AE2a promoter in PBMCs (–329a, –299a, and –291a), comparing PBC versus HV, OLD, and HV+OLD (i.e. non-PBC samples). (C)
Comparisons of average methylation rates of the PBC-associated minimal CpG cluster within AE2a promoter in PBMCs (–329a, –299a, and –291a), between PBC
and normal and diseased control samples. Significant p values (p <0.05) were obtained by Kruskall-Wallis test followed by Mann-Whitney U test. ALD, alcohol-
related liver disease; HVs, healthy blood-donors/volunteers; gDNA, genomic DNA; NAFLD, non-alcoholic fatty liver disease; OLDs, other liver diseases; PBC,
primary biliary cholangitis; PBMCs, peripheral blood mononuclear cells; PSC, primary sclerosing cholangitis; SBC, secondary biliary cirrhosis; TxH, toxic hepatitis;
VHC, viral hepatitis C.
Research Articleexpression of alternative AE2b2 and AE2b1 mRNAs in immune
cells we cultured lymphoblastoid T2 cells with and without the
demethylating agent 5-aza-2´-deoxycytidine and determined
mRNA levels. Baseline, T2 cells were found to express AE2a
mRNA but not alternative AE2 variants (Fig. 4), which concurredFig. 4. CpG methylation is involved in the dormant expression of alternative AE2
methylation rates of AE2 promoter regions in T2 cells are the following: 8.50 ± 8.2
alternate AE2b2 and AE2b1 regions (respectively). The levels of alternative AE2
determined by real-time PCR in cultured T2 cells treated for 48 h with either 5-aza-
GAPDH mRNA) are given as fold expression relative to values of the control with
vehicle. Significant p values (p <0.05) were obtained by Kruskall-Wallis test followed
JHEP Reports vowith the observations in PBMCs. Noticeably, T2 cells treated
with 5-aza-2´-deoxycytidine showed substantial expression of
alternative AE2b2 and AE2b1 mRNAs (Fig. 4), strongly suggesting
that demethylation leads to upregulated transcription from alter-
nate AE2b2/AE2b1 promoters. Moreover, 5-aza-2´-deoxycytidineb1 and AE2b2mRNAs in human lymphoblastoid T2 cells. Baseline, the overall
5% for the upstream AE2a region and 61.83 ± 26.11% and 94.14 ± 6.31% for the
b2 and AE2b1 mRNAs as well as those of the complete AE2a transcript were
2´-deoxycytidine, trichostatin-A, or just vehicle as control. Values (normalized for
vehicle alone. Significant p values refer to comparisons versus the control with
by Mann-Whitney U test.
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treatment was followed by a 3.6-fold increase in AE2a mRNA
levels (Fig. 4), most probably due to complete release of the
AE2a promoter from a baseline status of low-rate methylation
(average methylation rate of 8.50 ± 8.25%).
Finally, we tested a possible role of histone acetylation-
deacetylation for AE2 transcription and treated T2 cells with the
HDAC inhibitor trichostatin-A during 48 and 72 h. In contrast to
the effects observed with 5-aza-2´-deoxycytidine, no significant
changes in the levels of mRNAs were found with trichostatin-A
(see Fig. 4 depicting the results at 48 h).
Discussion
Here we report that significant epigenetic modifications of the
AE2 gene occur in the liver and PBMCs of patients with PBC,
which could explain the reduced gene expression in these
patients. Thus, we observed an increased CpG-cytosine methyla-
tion of AE2a, AE2b1 and AE2b2 proximal promoters in PBC livers
compared to normal and diseased controls. Hypermethylation
affects more intensely particular CpG sites in each promoter
region. ROC curve analysis found 2 minimal clusters of hyper-
methylated CpG-cytosines (1 comprised of 3 CpG-cytosines in
the upstream AE2a promoter, and another comprised of 4 CpG
sites in the alternate AE2b2 promoter, see Fig. 2), which could
specifically differentiate PBC from both normal and OLD samples.
Moreover, average methylation rates of combined CpG-cytosines
were found to inversely correlate with the levels of AE2 mRNAs
driven by respective promoter regions in the liver.
Analogous data and correlations were observed in PBMCs but
referred only to the upstream AE2a promoter and AE2a transcript.
ROC curve analyses also found a minimal cluster composed by 3
CpG-cytosines in the AE2a promoter, the average methylation of
which could specifically differentiate PBMC samples of patients
with PBC from normal and OLD peripheral immune cells (Fig. 3).
On the other hand, alternate AE2b2/AE2b1 promoter regions were
ascertained to be silent not only in PBC but also in normal and
diseased PBMCs. These regions show constitutive increased CpG-
cytosine methylation that presumably prevents the expression of
alternative AE2 transcripts. This view is strongly supported by our
findings in lymphoblastoid T2 cells, in which dormant expression
of AE2b2 and AE2b1 mRNAs could be activated when T2 cells
were treatedwith the demethylating agent 5-aza-2´-deoxycytidine.
Interestingly, such a treatment also increased the expression of
AE2a mRNA, revealing that further release from basal low-rate
methylation in the AE2a proximal promoter might result in ampli-
fied transcriptional activity. Treatment with trichostatin-A, how-
ever, had no effect on AE2 promoter activities in T2 cells, which
suggests that histone deacetylation is poorly involved in
dormant alternative expression of AE2 in these immune cells.
Altogether, our findings indicate that hypermethylation of the
AE2 promoter regions might be an important mechanism leading
to decreased expression of AE2 mRNAs in the liver and PBMCs
of patients with PBC. It may be speculated that methylation of
CpG-cytosines located in the vicinity of particular motifs might pre-
clude the recruitment of DNA binding proteins and cause transcrip-
tional inactivation.35,36 Interestingly, the minimal cluster of CpG-
cytosines in the AE2a promoter that are hypermethylated in PBC
livers spans near the equivalent minimal cluster detected in
PBMCs from patients with PBC; for instance, most AE2a-CpG sites
with increasedmethylation in liver andPBMCsamples frompatients
with PBC locate close to Sp1 and ERG-1/WT1 motifs (Figs. 1 and 3).
Consequently, the clusters detected in the AE2a promoter region (1JHEP Reports voin liver samples and another in PBMCs from patients with PBC)
can affect similarmotifs in the promoter. It might also be speculated
that methylated cytosines serve as docking sites for methyl-CpG-
binding domain (MBD) proteins and repress transcription indirectly
via recruitment of corepressors and chromatin modification.35,36
Transcription from alternate AE2b2 and AE2b1 overlapping pro-
moter regions is quite restricted to the liver and kidney in humans,
when compared to rodents.39 Most probably, liver restriction is
connected tomotifs for liver-enriched and related transcription fac-
tors like HNF1, CBP, and glucocorticoid receptor encountered in
those overlapping promoter regions in the human gene.25,42 Of
notice, most AE2b2/AE2b1-CpG sites characteristically hypermethy-
lated in the liver of PBC patients locate in the neighborhood of sites
andmotifs for those liver-related transcription factors.39 In fact, the
minimal cluster of hypermethylated CpG-cytosines in the AE2b2
alternate promoter which discriminates PBC livers from normal
liver samples and OLD samples spans a region encompassing an
HNF1 site25,42 and an upstream HNF4 motif.39
In the liver, AE2 is involved in biliary bicarbonate secretion.26,27
This exchanger protein is therefore directly responsible for creating
the "bicarbonate umbrella" along the biliary tree that protects cho-
langiocytes from the proapoptotic effects of bile salts by maintain-
ing them deprotonated.45 In a context of reduced liver AE2
expression and AE2 deficiency, there may occur defective bicarbo-
nate umbrella and subsequent entry of protonated bile salts into
cholangiocytes (concisely and nicely reviewed in ref.12). Entry of
highly hydrophobic bile salts can promote reactive oxygen species
(ROS) production, and lead to enhanced inflammatory cytokine
and chemokine responses.46 ROS production might also contribute
to further decreasing AE2 expression.46 On the other hand, AE2
knockdown in vivo was shown to result in increased ROS produc-
tion in the liver.46 Additionally, AE2 knockdown experiments in
cholangiocytes led to intracellular accumulation of bicarbonate
and increased expression and activity of soluble adenylyl cyclase
(sAC).47 This bicarbonate sensor was found to sensitize cholangio-
cytes to bile salt-induced apoptosis through the intrinsic apoptotic
pathway.47 Interestingly, cholangiocytes were previously reported
to translocate immunologically intact PDC-E2 to apoptotic bodies
and create an apotope,48 that may favor the development of
AMAs. The triad of bile-duct cell derived apotopes, macrophages
from patients with PBC, and AMAs were also found to trigger an
intense production of proinflammatory cytokines.49 More recently,
cultured human cholangiocytes treated with proinflammatory
cytokines typically overexpressed in PBC livers (such as IL8, IL12,
IL17, IL18, and TNF-α) were shown to enhance the expression of
miR-506, that induced PBC-like features in these bile-duct cells
and promoted immune activation.50 Noticeably, bile-duct cells of
PBC liverswere described to upregulatemiR-506, which can inhibit
translation of AE2 transcripts and contribute to further decreasing
the expression of AE2 protein.34
Previously reported experiments in animalmodels showing that
highly hydrophobic bile saltsmight decrease AE2mRNA expression
through ROS production46 seemingly have a correlate in the subset
of our current diseased liver control specimens fromseverely chole-
static patients (Fig. S2). In this subset of diseased control samples,
we foundmarkedly low levels of AE2mRNAs despite AE2 promoter
methylation being comparable to that in normal-liver control sam-
ples (as well as to those in diseased control samples from patients
with OLDs and moderate cholestasis; Fig. S3). In PBC livers, how-
ever, promoter methylation was significantly increased (Fig. S3)
and AE2 mRNA levels were consistently diminished (Fig. S2),
regardless of whether patients had severe or moderate cholestasis.l. 1 | 145–153 151
Research ArticleAltogether, these data support the notion that diminished AE2 gene
expression in PBC livers primarily results from increased AE2 CpG
methylation, whereas in OLD specimens from severely cholestatic
patients, the diminished liver expression of AE2 gene occurs as a
direct consequence of the elevated levels of hydrophobic bile
salts, unrelated to CpG methylation. Our earlier findings in Ae2-
knockout mice,28 as well as the aforementioned AE2 knockdown
experiments (both in vivo46 and in bile-duct cells47), clearly show
that a primary failure in AE2 gene expression may result in detri-
mental cascades in the liver.
In PBMCs, AE2 is involved in intracellular pH regulation and
immunological homeostasis.24,29,30 Thus AE2 promoter hyper-
methylation and deficient AE2 mRNA expression in patients with
PBCmay contribute to the immunedysregulation PBCpatients typi-
cally have. Indeed the particular predisposition to activation of
immune cells against bile-duct cells in PBC resembles the dysfunc-
tions of T cells observed in our Ae2-knockout animal model, in
which they interact in the liver with highly immunogenic AE2-
deficient bile-duct cells.28–30 In contrast to PBC, no autoimmune
cholangitis is expected to develop in severely cholestatic patients
with OLDs despite dramatically decreased AE2 mRNA levels in the
liver, since PBMCsdonot appear to be equally affected by the severe
cholestasis. Thus, the idiosyncratic conjunction of anomalies puta-
tively streaming from AE2 hypermethylation in both the liver and
PBMCs in patients with PBC may constitute a crucial 2-arms prere-
quisite for the development of autoimmune cholangitis (Fig. S6),
and provide relevant clues to unravel the enigmatic pathogenesis
of the disease.JHEP Reports voA series of epigenetic alterations on the X chromosome and
autosomal chromosomes were previously reported in PBC.51–53
Some genes appear hypermethylated while other genes are with
decreased DNA methylation, indicating that hypermethylation is
not a widespread phenomenon in PBC. Therefore, the increased
methylation of the AE2 gene currently observed in our study in
PBC samples might be viewed as disease specific in the context of
additional epigenetic modifications. Disclosing the cause(s) of
such modifications in PBC should be a priority for the related
studies in the near future. Certainly, PBC is a multifactorial liver
disease that may ensue from highly complex interactions
between genetic and environmental factors, as stressed by
GWAS data and more conventional genetic and epidemiological
studies.6,54–56 Environmental exposures may result in epigenetic
modifications, particularly DNA methylation.57 Smoking, for
instance, which has been associated with high risk of PBC,56,58
was also related with increased DNA-methyltransferase expres-
sion.59 Therefore, DNA methylation affecting AE2 and additional
genes, may constitute a link between genetic and environmental
risk factors in PBC pathogenesis.
In summary, AE2 deficiency in patients with PBC may render
cholangiocytes more immunogenic and susceptible to autoim-
mune attack, whereas an equivalent defect in PBMCs may alter
immunological homeostasis.29,30 Additional identified (and not
yet identified) genetic and epigenetic modifications in genes per-
tinent to immunity may further boost a pivotal contribution of
AE2 deficiency, and lead to immune dysregulation and autoim-
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